• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

皮肤痛觉过敏作为慢性偏头痛治疗反应的预测指标:一项队列研究。

Cutaneous allodynia as predictor for treatment response in chronic migraine: a cohort study.

机构信息

Department of Neurology, Leiden University Medical Centre, PO Box 9600, 2300 RC, Leiden, The Netherlands.

Department Radiology, Leiden University Medical Centre, Leiden, The Netherlands.

出版信息

J Headache Pain. 2023 Aug 30;24(1):118. doi: 10.1186/s10194-023-01651-9.

DOI:10.1186/s10194-023-01651-9
PMID:37644420
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10466691/
Abstract

BACKGROUND

Central sensitisation is an important mechanism in migraine chronification. It is presumed to occur in second and third order neurons sequentially, resulting in an analogous spatial distribution of cutaneous allodynia with cephalic and extracephalic symptoms. We investigated whether allodynia, and its subtypes based on spatial distribution and type of stimulus, predict response to treatment in chronic migraine patients.

METHODS

This study was conducted as part of the CHARM study (NTR3440), a randomized, double-blind, placebo-controlled trial in chronic migraine patients with medication overuse. We included 173 patients. The presence of cutaneous allodynia at baseline was established with the Allodynia Symptom Checklist. Primary endpoint was reversion from chronic to episodic migraine.

RESULTS

Of all patients, 74.6% reported cutaneous allodynia. Absence of allodynia compared to presence of allodynia was predictive for reversion from chronic to episodic migraine, odds ratio (OR): 2.45 (95% CI: 1.03-5.84), p = 0.042. The predictive value was more pronounced when subdivided for spatial distribution, for participants without allodynia versus cephalic (OR: 4.16 (95% CI: 1.21-14.30), p = 0.024) and extracephalic (OR: 7.32 (95% CI: 1.98- 27.11), p = 0.003) allodynia. Mechanical, but not thermal, allodynia, was associated with outcome.

CONCLUSIONS

Cutaneous allodynia, an important marker for central sensitization, likely has predictive value for treatment response in chronic migraine.

摘要

背景

中枢敏化是偏头痛慢性化的重要机制。它被认为依次发生在第二和第三级神经元中,导致类似的头皮和颅外症状的皮肤感觉过敏的空间分布。我们研究了感觉过敏及其基于空间分布和刺激类型的亚型是否可以预测慢性偏头痛患者对治疗的反应。

方法

这项研究是 CHARM 研究(NTR3440)的一部分,这是一项针对药物过度使用的慢性偏头痛患者的随机、双盲、安慰剂对照试验。我们纳入了 173 名患者。基线时使用感觉过敏症状检查表确定皮肤感觉过敏的存在。主要终点是从慢性偏头痛转为发作性偏头痛。

结果

所有患者中有 74.6%报告了皮肤感觉过敏。无感觉过敏与有感觉过敏相比,更能预测从慢性偏头痛转为发作性偏头痛,优势比(OR):2.45(95% CI:1.03-5.84),p=0.042。当按空间分布细分时,预测价值更明显,无感觉过敏的患者与头皮(OR:4.16(95% CI:1.21-14.30),p=0.024)和颅外(OR:7.32(95% CI:1.98-27.11),p=0.003)感觉过敏相比,OR 更高。机械性但不是热感觉过敏与结果相关。

结论

皮肤感觉过敏是中枢敏化的一个重要标志物,可能对慢性偏头痛的治疗反应具有预测价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85c0/10466691/f71dfdbb544b/10194_2023_1651_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85c0/10466691/8fc414acf0de/10194_2023_1651_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85c0/10466691/f71dfdbb544b/10194_2023_1651_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85c0/10466691/8fc414acf0de/10194_2023_1651_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85c0/10466691/f71dfdbb544b/10194_2023_1651_Fig2_HTML.jpg

相似文献

1
Cutaneous allodynia as predictor for treatment response in chronic migraine: a cohort study.皮肤痛觉过敏作为慢性偏头痛治疗反应的预测指标:一项队列研究。
J Headache Pain. 2023 Aug 30;24(1):118. doi: 10.1186/s10194-023-01651-9.
2
Central sensitisation and cutaneous allodynia in migraine: implications for treatment.偏头痛中的中枢敏化和皮肤异常性疼痛:对治疗的启示。
CNS Drugs. 2004;18(6):337-42. doi: 10.2165/00023210-200418060-00001.
3
Effects of pregabalin on central sensitization in patients with migraine.普瑞巴林对偏头痛患者中枢敏化的影响。
Int J Clin Pharmacol Ther. 2015 Apr;53(4):277-83. doi: 10.5414/CP202205.
4
Cutaneous allodynia in patients with episodic migraine.发作性偏头痛患者的皮肤痛觉过敏。
Neurol Sci. 2013 Aug;34(8):1397-402. doi: 10.1007/s10072-012-1249-9. Epub 2012 Nov 23.
5
Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache.Ubrogepant 不会在药物过度使用性头痛的临床前模型中引起潜在致敏。
Cephalalgia. 2020 Aug;40(9):892-902. doi: 10.1177/0333102420938652. Epub 2020 Jul 2.
6
Cutaneous allodynia is more frequent in chronic migraine, and its presence and severity seems to be more associated with the duration of the disease.皮肤异常性疼痛在慢性偏头痛中更为常见,其出现及严重程度似乎与疾病持续时间更为相关。
Arq Neuropsiquiatr. 2017 Mar;75(3):153-159. doi: 10.1590/0004-282X20170015.
7
Pre-treatment non-ictal cephalic allodynia identifies responders to prophylactic treatment of chronic and episodic migraine patients with galcanezumab: A prospective quantitative sensory testing study (NCT04271202).前瞻性定量感觉测试研究(NCT04271202):治疗前非发作性头部触诱发痛可识别加奈珠单抗预防治疗慢性和发作性偏头痛患者的应答者。
Cephalalgia. 2023 Mar;43(3):3331024221147881. doi: 10.1177/03331024221147881.
8
General trigeminospinal central sensitization and impaired descending pain inhibitory controls contribute to migraine progression.一般的三叉神经脊髓中枢敏化和下行性疼痛抑制控制受损促成偏头痛进展。
Pain. 2014 Jul;155(7):1196-1205. doi: 10.1016/j.pain.2014.03.001. Epub 2014 Mar 12.
9
Concomitant Migraine and Temporomandibular Disorders are Associated With Higher Heat Pain Hyperalgesia and Cephalic Cutaneous Allodynia.偏头痛与颞下颌关节紊乱症并存与更高的热痛超敏反应和头部皮肤异常性疼痛相关。
Clin J Pain. 2016 Oct;32(10):882-8. doi: 10.1097/AJP.0000000000000369.
10
Are there differences between cephalic and extracephalic cutaneous allodynia in migraine patients?偏头痛患者的头部和头部外皮肤痛觉过敏有区别吗?
Cephalalgia. 2010 Jul;30(7):881-6. doi: 10.1111/j.1468-2982.2009.02008.x.

引用本文的文献

1
Pain Coping in Patients With Chronic Migraine and Medication Overuse Headache.慢性偏头痛和药物过度使用性头痛患者的疼痛应对
Brain Behav. 2025 Aug;15(8):e70739. doi: 10.1002/brb3.70739.
2
Risk Factors and Consequences of Cutaneous Allodynia among Individuals with Migraine: A Scoping Review.偏头痛患者皮肤异常性疼痛的危险因素及后果:一项范围综述
Curr Pain Headache Rep. 2025 Jul 22;29(1):102. doi: 10.1007/s11916-025-01417-9.
3
[Huoxue Shufeng Granule alleviates central sensitization in chronic migraine mice via TLR4/NF-κB inflammatory pathway].

本文引用的文献

1
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients.抗 CGRP 单克隆抗体治疗反应的预测因素:864 例偏头痛患者的 24 周、多中心、前瞻性研究。
J Headache Pain. 2022 Nov 1;23(1):138. doi: 10.1186/s10194-022-01498-6.
2
Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months.曲坦类药物过量使用性偏头痛中抗 CGRP 单克隆抗体:6 个月时的真实疗效和反应预测因子。
J Headache Pain. 2021 Oct 7;22(1):120. doi: 10.1186/s10194-021-01328-1.
3
Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study.
[活血疏风颗粒通过TLR4/NF-κB炎症通路减轻慢性偏头痛小鼠的中枢敏化]
Nan Fang Yi Ke Da Xue Xue Bao. 2025 May 20;45(5):986-994. doi: 10.12122/j.issn.1673-4254.2025.05.11.
4
Validation of an 8-item self-administered questionnaire for assessing migraine-related sensory hypersensitivities (MHQ-8).用于评估偏头痛相关感觉超敏反应的8项自填式问卷(MHQ-8)的验证
J Headache Pain. 2025 May 26;26(1):128. doi: 10.1186/s10194-025-02067-3.
5
Cut-Off Values Able to Identify Migraine Patients With Increased Pressure-Pain Sensitivity Independent of the Migraine Cycle Through a Single Assessment: A Secondary Analysis of a Multicentre, Cross-Sectional, Observational Study.通过单次评估能够识别出与偏头痛周期无关的压力疼痛敏感性增加的偏头痛患者的截断值:一项多中心、横断面、观察性研究的二次分析。
Eur J Pain. 2025 Feb;29(2):e4787. doi: 10.1002/ejp.4787.
6
General physical impairments in migraine patients beyond cervical function.偏头痛患者除颈椎功能外的一般身体损伤。
Sci Rep. 2024 Dec 28;14(1):30916. doi: 10.1038/s41598-024-81841-w.
7
Pain profiling in migraine: a systematic review of Quantitative Sensory Testing (QST), Conditioned Pain Modulation (CPM), and Corneal Confocal Microscopy (CCM).偏头痛的疼痛特征分析:定量感觉测试(QST)、条件性疼痛调制(CPM)和角膜共聚焦显微镜检查(CCM)的系统评价
J Headache Pain. 2024 Dec 19;25(1):224. doi: 10.1186/s10194-024-01932-x.
8
Reducing the Impact of Headache and Allodynia Score in Chronic Migraine: An Exploratory Analysis from the Real-World Effectiveness of Anti-CGRP Monoclonal Antibodies Compared to Onabotulinum Toxin A (RAMO) Study.降低慢性偏头痛头痛和触诱发痛评分的影响:比较抗 CGRP 单克隆抗体与肉毒毒素 A(RAMO)研究的真实世界疗效的探索性分析。
Toxins (Basel). 2024 Apr 7;16(4):178. doi: 10.3390/toxins16040178.
依瑞奈玛单抗治疗慢性偏头痛疗效不佳的心理预测因素:一项开放标签长期前瞻性研究的数据。
J Headache Pain. 2021 Oct 2;22(1):114. doi: 10.1186/s10194-021-01333-4.
4
Efficacy of erenumab in chronic migraine patients with and without ictal allodynia.依瑞奈尤单抗治疗伴有和不伴有发作性触诱发痛的慢性偏头痛患者的疗效。
Cephalalgia. 2021 Oct;41(11-12):1152-1160. doi: 10.1177/03331024211010305. Epub 2021 May 13.
5
Pathophysiology, prevention, and treatment of medication overuse headache.药物过度使用性头痛的病理生理学、预防和治疗。
Lancet Neurol. 2019 Sep;18(9):891-902. doi: 10.1016/S1474-4422(19)30146-2. Epub 2019 Jun 4.
6
Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.对《欧洲头痛联盟关于使用作用于降钙素基因相关肽或其受体的单克隆抗体预防偏头痛的指南》的勘误
J Headache Pain. 2019 May 23;20(1):58. doi: 10.1186/s10194-019-0972-5.
7
Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial.依瑞奈尤单抗治疗药物过度使用性偏头痛的疗效:一项随机试验的亚组分析。
Neurology. 2019 May 14;92(20):e2309-e2320. doi: 10.1212/WNL.0000000000007497. Epub 2019 Apr 17.
8
Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial.慢性偏头痛药物过度使用患者的急性撤药与肉毒毒素 A:一项双盲随机对照试验。
Brain. 2019 May 1;142(5):1203-1214. doi: 10.1093/brain/awz052.
9
Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity.硝化甘油引发曲坦类药物反应性颅神经病和三叉神经神经元敏化。
Brain. 2019 Jan 1;142(1):103-119. doi: 10.1093/brain/awy313.
10
Dissecting out migraine complexity through comprehensive analysis of allodynia.通过对痛觉过敏的全面分析剖析偏头痛的复杂性。
Brain. 2019 Jan 1;142(1):5-8. doi: 10.1093/brain/awy315.